Strukmyer Medical was cited for current good manufacturing practice violations after FDA found repeated microbial contamination in water used to make OTC drugs.
What happened
FDA inspected the drug manufacturing facility from July 8 to August 1, 2024. The agency found that over 60 times between November 1, 2022 and July 10, 2024, the firm isolated objectionable microorganisms from its water system, which was used as an ingredient to make over-the-counter drug products for wounds and burns. FDA also found inadequate testing of incoming components, inadequate cleaning, and inadequate quality unit oversight.
What FDA found
The firm did not thoroughly investigate repeated harmful microorganism findings in its water system or determine root causes and prevent recurrence.
21 CFR 211.192The firm did not test each component lot for identity and conformity and did not validate supplier test results, including failing to test each glycerin lot for diethylene glycol and ethylene glycol.
21 CFR 211.84(d)(1) and 211.84(d)(2)The firm did not show its cleaning and disinfection removed all contaminants from equipment, because cleaning validation only tested for Gram-negative bacteria.
21 CFR 211.67(a)The firm's quality unit did not ensure contract laboratory chemical and microbial test methods were adequately validated or verified.
21 CFR 211.22(a)The firm's drug products are adulterated because its manufacturing methods, facilities, or controls did not conform to CGMP.
FD&C Act section 501(a)(2)(B) [21 U.S.C. 351(a)(2)(B)]
What FDA wants
FDA tells the company to correct the violations promptly and respond in writing within 15 working days with corrective actions, risk assessments, investigations, and remediation plans; FDA also recommends a qualified CGMP consultant.
Who should pay attention
- brands that buy finished OTC drug products from this contract manufacturer
- companies using glycerin or other high-risk components in drug products
- quality teams that oversee contract laboratories and water systems
This is a summary. Read the original letter on fda.gov.